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INTRODUCTION
Since the first AIDS cases were described, a
high prevalence of gastrointestinal alterations has
been reported, especially diarrhea associated with
parasitosis.
This became more evident when the
appearance of a syndrome named “Slim Disease”,
characterized by an intense weight loss
accompanied by chronic diarrhea, prolonged fever
and diffuse muscle weakness, was observed in
Africa, especially in Uganda.
1,2,3
 Studies conducted
in Zaire and Uganda have shown the presence of
some pathogenic agents responsible for the “Slim
Disease”, such as Isospora, Cryptosporidium,
Salmonella, Shigella and Campylobacter species,
amounting to a prevalence of 60 to 80%.
4
 “Slim
Disease” has been observed in advanced stages
of HIV infection. The expression “Wasting
Syndrome” was adopted in substitution by WHO
in 1988 on the basis of criteria laid down by the
CDC.
2
Thus, where as infections in the gastrointestinal
tract play a critical role in AIDS pathogenesis and
diarrheic diseases assume a prominent role,
reaching a rate of up to 50% in developed
countries, in developing countries there have been
reports of incidence of up to 95%, as in Haiti and
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the African continent.
5
Amongst the causes of diarrhea in developing
countries, those of a parasitic origin are prominent
in patients with AIDS.
Opportunistic infections caused by intestinal
parasites also vary according to the geographical
area and the endemic levels in each location.
The progressive decline of immunological and
mucous defense mechanisms predisposes patients
to early, intermediary and late gastrointestinal
manifestations of HIV infection.
6
 At later stages of
the disease, the alterations in non-specific defense
mechanisms in the production of Ig A and the
reduction in local immune cell response also
progress, thus increasing the susceptibility to a
number of intestinal opportunistic pathogens,
among which Cryptosporidium parvum, Isospora
belli and Microsporidia species are the most
prominent.
7
After the emergence of AIDS, these parasites,
until then known solely in veterinary medicine, were
no longer considered as commensal organisms and
are nowadays recognized as opportunistic
pathogens common to these patients.  Infections
by these agents constitute a major secondary
aggravating factor of the disease, often responsible
for worsening the general health conditions, due
to manifestations of diarrhea which are difficult to
control, sometimes resulting in the death of the
patient.
CRYPTOSPORIDIASIS
Cryptosporidiasis, a disease caused by an
intracellular protozoan named Cryptosporidium sp,
was described for the first time in 1907 by Tyzzer.
This parasite was considered a commensal up to
1975, when it was identified as the cause of
diarrhea in animals.
8
The first manifestation of cryptosporidiasis
was reported by Nine et al. in 1976, and the
disease became a major concern when the
notification of the first 21 patients was given, 14
of whom died of chronic diarrhea caused by
Cryptosporidium sp infection.
9
It is worth noting that outbreaks of epidemic
linked to contaminated water are of extreme
importance for the dissemination of this parasite such
as the 1993 Milwaukee (USA) cryptosporidiasis
outbreak, in which 403,000 human cases were
reported, thereby becoming a relevant public health
concern.
10-12
 After this outbreak, it was recommended
that immunocompromised patients should be
extremely careful with water, foodstuffs and contact
with animals.
Cryptosporidiasis is distributed over all
continents. In Haiti and the African continent the
prevalence is 50%,
13
 while in the USA it ranges from
3 to 4%.
14
In Brazil, due to the continental size of the
country, the rates of incidence vary with the location.
In the city of São Paulo, for instance, reports have
referred to levels around 12.1 to 24.44%.
15-17
However, the latest epidemiological report on
Brazil, dated February 1998, shows a
cryptosporidiasis rate of only 3.5%.
18
Cryptosporidiasis in AIDS patients usually
causes chronic, bulky and intermittent diarrhea, with
liquid non-bloody stools, accompanied by pain and
abdominal colic, and a noticeable loss of weight
can be observed.
8
Asymptomatic cases are rarely described,
occurring mostly in developing countries with
patients showing milder immunodeficiency.
19,20
Extraintestinal manifestations have been
clearly described in the literature, especially in the
gall bladder, biliary ducts and pancreas, leading
to conditions such as papillary stenosis, sclerosing
cholangitis and acalculous cholecystitis. The
respiratory tract can also be affected with
manifestations of chronic bronchitis.
21,22
The intensity and duration of diarrhea in
cryptosporidiosis cases is closely associated with
the CD4+ T cell counts. This is well demonstrated
in a classic study on HIV-infected patients with CD4+
cell counts higher than 180/mm
3
 who displayed
clinical healing over a period of four weeks, while
87% of the patients presenting more severe
immunosuppression, with CD4+ counts lower than
140/mm
3
, presented persistent and hard-to-control
diarrhea.
23
Laboratory diagnosis of cryptosporidiosis is
easy to accomplish, using special staining
techniques such as the Kinyoun (modified Ziehl
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Neelsen) and auramine-rhodamine methods, via
the detection of reddish-stained Cryptosporidium
oocysts.
24
 More sophisticated diagnostic techniques
using monoclonal antibodies are already available,
such as ELISA and immunofluorescence, with high
sensitivity and specificity.
25-27
 The treatment is
controversial, with rehydration via an appropriate
liquid balance and the maintenance of the patient’s
nutritional condition being recommended. There
should be careful monitoring and administration
of antidiarrheic drugs when needed.
28
 Several
treatments are available but they have not shown
significant clinical efficiency. Studies have been
conducted with hyperimmune bovine colostrum,
letrazuril and diclazuril (veterinary medicine drugs),
spiramicyn and more recently azithromicyn,
paromomycin, octreotide and roxithromycin.
29-31
ISOSPORIASIS
Isospora belli is a coccidium described for
the first time in 1915 by Woodcock and later by
Wenyon in 1923.
32
 It is found in tropical and
subtropical areas and is endemic in South America,
Africa and in Southern Asia,
33
 with an occurrence
rate of 15% in Haiti,
33
 0.2% in the USA
34
 and
1.8% in Brazil.
18
Higher rates of isosporiasis in Brazil have
been reported in AIDS patients living in Santos and
in São Paulo, with a prevalence of 9.9% and
6.67%, respectively.
17,35 
The lower prevalence of
Isosporiasis may be ascribed to the secondary
prophylaxis for pneumocystosis through
administration of sulfamethoxazole-trimethoprim
during the course of AIDS, since Isospora belli is
sensitive to this therapy.
36
The diarrheic condition is also noteworthy
and is accompanied by fever, intestinal colic,
anorexia, abdominal pain, loss of weight and
peripheral eosinophilia.
37
Isosporiasis can also show extraintestinal
dissemination features, affecting the mesenteric,
periaortic, mediastinal and tracheobronchial lymph
nodes.
38,39
 It may also be related to biliary disease,
causing manifestations of acalculous cholecystitis.
37
Isospora belli differs morphologically from
Cryptosporidium sp not only because of its intrinsic
morphology (elliptical oocyst measuring 22 x 15
µm in diameter, containing two sporocysts with four
sporozooites), but also for the intracellular location
in the absorptive cell, while Cryptosporidium is
restricted to the brush borders, immediately under
the apical membrane of absorptive cells.
40
Laboratory diagnosis is carried out in the
same way as for Cryptosporidium parvum, using
the Kinyoun and auramine-rhodamine techniques,
41
although common processes such as Faust’s are
often enough for the diagnosis. The special
coloration thus becomes a further diagnostic
element for finding the parasite.
The therapeutic recommendation for
isosporiasis is the administration of
sulfamethoxazole-trimethoprim for 10 days,
followed by prophylaxis for a further three weeks.
This leads to a reduction in the number of
discharges and the recovery of body weight.
36
In recurrent situations or in non-responding
patients it is necessary to administer other drugs
such as pyrimethamine, in isolation or in
association with sulfadiazine,
42
 roxithromycin
43
and metronidazole.
44
 Drugs such as tetracycline,
ampicillin, nitrofurantoin, quinacrine and
furazolidone have already been used but showed
no therapeutic success.
34
MICROSPORIDIASIS
The third major group of intestinal pathogens
to be reported are the microsporidia, which are
strictly intracellular protozoa, spore-producing and
with great variety of genera and species. They have
widespread distribution and over 400 cases of
patients with co-infection of microsporidia and HIV
have been reported. The major etiologic agent is
Enterocytozoon bieneusi.
45
The first description of intestinal
microsporidiasis in an HIV-positive patient
occurred in France.
46
 The first description of this
condition in Brazil dates back to 1993, with
cases having occurring in Rio de Janeiro, São
Paulo and Ceará.
47-50
The world prevalence of intestinal
microsporidiasis ranges between 7 and 50%.
51
 In
Rio de Janeiro a recent study applying the direct
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technique for detection of microsporidian spores
in the stool samples of 140 HIV-positive patients
showed that the rate of prevalence of intestinal
microsporidiasis was 17.86%.
52
 The fact that these
cases have only recently appeared can be
explained by the diagnostic difficulty, as electronic
microscopy is required for confirmation of the
presence of the parasite. In contrast, in the city of
São Paulo only 1.3% of microsporidian spores were
shown up in patients with AIDS and chronic
diarrhea via the modified trichrome staining
method.
52A
Optical microscopy methods, such as the
chromotrope method, were then proposed whereby
spores would appear as oval-shaped and stained
pink or pale red.
53
 This technique has been
improved and named Gram-chromotrope. Fecal
sample smears are stained in Gram’s stain, followed
by a chromotrope solution.
54
Chronic diarrhea and/or biliary disease
manifestations in HIV-infected individuals with
CD4+ T cells of between 50 and 100/mm
3
 may
suggest microsporidiosis. Transmission is unknown
to date, but there have been reports of congenital
transmission and via inhalation of airborne
spores.
51
Regarding treatment, albendazole has been
the most promising drug for handling intestinal
microsporidiasis. 
55-57
GIARDIASIS AND AMEBIASIS
The protozoans Giardia lamblia and
Entamoeba histolytica are important causes of acute
diarrhea in homosexual males, even for those that
are not HIV-positive. Together with Campylobacter,
Salmonella, Shiguella and Yersinia they cause high
frequencies of enteritis, colitis and proctitis.
58
Statistical data found in the literature are
rather divergent, but the incidence of these
protozoans amongst the homosexual populations
of large cities, such as New York, Los Angeles,
San Francisco and Toronto is quite high.
59
The prevalence of Entamoeba histolytica in
HIV-negative homosexual patients in the USA
ranges between 21 and 32%, and is around 12%
in the United Kingdom.
60
A study performed in Los Angeles with 100
HIV-positive patients, mostly homosexuals, showed
a prevalence rate of 55% for giardiasis and 3%
for amoebiasis.
61
In France, studies focused upon the
prevalence of intestinal parasitosis showed a high
frequency of protozoan species in AIDS patients,
and the rates of Giardia lamblia and Entamoeba
histolytica were 5.8% and 2%, respectively 
62
.
Previous studies demonstrated that giardiasis
incidence does not differ amongst HIV-positive and
negative patient populations.
63
Infection with Giardia lamblia and HIV
amongst homosexual males is correlated with
enteritis or enterocolitis, but no histological study
of the colonic mucosa has yet been carried out.
64
In Brazil, examination of 771 fecal samples
from AIDS patients living in São Paulo, performed
under the program for the control and prevention
of AIDS, have shown rates of 5.18% and 8.49%
of amebiasis and giardiasis, respectively.
15
 In a
recent study in the city of São Paulo analyzing
patients with more severe immunodeficiency, E.
histolytica was not observed but G. lamblia cysts
were seen in about 27% of the examined patients.
17
Despite this high prevalence, classical
protozoa such as Giardia Lamblia and Entamoeba
histolytica are less frequent as causes of severe
illnesses in HIV-infected patients, when compared
with Microsporidia, Isospora belli and
Cryptosporidium parvum and they are not
considered as opportunistic infections in AIDS.
Amebiasis may present with invasive
characteristics, but this has rarely been reported in
the literature.
65
More recently, in Recife, a study was
conducted to evaluate invasive amebiasis in AIDS
patients. Seventy four patients were examined, out
of which 54 had diarrhea but Entamoeba histolytica
was found in only one patient (1,3%) and practically
an absence of invasive amoebiasis.
66
STRONGYLOIDIASIS
Among the helminths in association with
AIDS, there is no doubt that the most important
pathogen is Strongyloides stercoralis, which was
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first described in 1876 by Normand, after necropsy
of patients with diarrhea in from Cochin-China,
then an autonomous region of China.
67
This geohelminth presents its major effects in
immunodepressed patients, leading to the
dissemination of the infection. This occurs in
transplanted patients, individuals presenting
malnutrition and patients submitted to prolonged
use of corticosteroids, suffering from leukemia,
lymphomas or AIDS.
68,69
Despite the possibility of dissemination of this
helminth in HIV-positive patients, only 14 cases had
been reported by 1994 in the international
literature.
70
A case of massive infection by Strongyloides
stercoralis in AIDS patients in São Paulo was
recently reported, presenting the nematode even
in sputum samples.
71
The clinical syndrome of disseminated
strongyloidiasis is characterized by gastrointestinal
signs and symptoms, such as nausea, vomiting,
meteorism, anorexia and diarrhea, alternating with
periods of intestinal constipation and secondary
infections. Respiratory symptoms such as dyspnea,
hemoptysis, coughing, or manifestations of asthma
and even extensive pneumonia, may be observed.
At the same time, the patient can present fever,
cachexia and loss of weight.
72, 73
In immunosuppressed patients, self-infestation
is speeded up and a large number of larvae are
released, causing the dissemination of the
infection.
74
In Brazil, the prevalence of strongyloidiasis
in HIV-positive patients is around 4 to 15%, in
comparison with 1.4% in the general
population.
15,17,69
Laboratory diagnosis is based upon the
Baerman-Moraes or Rugai-Mattos-Brisola methods,
presenting as their basic principle the thermo and
hydrotropism of Strongyloides stercoralis larvae
seen in stool samples.
67
Strongyloides stercoralis larvae may also be
detected in aspirated duodenal material, sputum,
broncho-alveolar lavage, cervicovaginal cytology,
cerebrospinal fluid and gastric cytology.
74
Generally, the search for Strongyloides
stercoralis, even in isolated samples, shows a
positivity of 30% in immunocompromised
individuals with AIDS. When three or more samples
are taken, this positivity reaches levels as high as
80%.
67
Thiabendazole is considered the drug of
choice for treating strongyloidiasis, in
immunosuppressed individuals. The rates of
eradication by this anti-helminth drug can reach
levels as high as 90%.
67,68,72
 Other
chemotherapy agents that may be used include
albendazole and cambendazole.
In Strongyloides stercoralis hyperinfection
cases, treatment with thiabendazole may be used
for prolonged periods, followed by maintenance
doses. Often, eradication is difficult.
70,71
 Another
option in these cases is the administration of
ivermectin, a drug used for onchocerciasis, with
healing rates around 94%.
70,75,76
 This drug is not
yet available in Brazil.
OTHER PARASITES
Other helminths such as Ascaris lumbricoides
(3.52%), Trichiuris trichiura (4.14%), Ancylostomidae
(2.69%), Enterobius vermicularis (0.21%),
Schistosoma mansoni (1.66%), Taenia sp (0.21%)
and Hymenolepis nana (10.41%) have shown lesser
frequency and importance in AIDS patients.
15
Several other intestinal parasitoses may lead
to aggravation and/or dissemination of the course
of AIDS. Protozoa such as Cyclospora sp and
Blastocystis hominis have arisen, which may also
cause major diarrhea manifestations.
Blastocystis hominis is a potentially
pathogenic parasite, more predominant in male
homosexuals than in other population groups, and
its occurrence is not higher in individuals suffering
from digestive disturbances.
77
 It has been isolated
in human feces with a frequency ranging from 1 to
60% in individuals from different parts of the world
and exposure to contaminated water contributes
to the increase of this parasitosis.
78
The association of Blastocystis hominis with
immunodepression has been well-documented,
chiefly in diabetic and leukemic patients.
79,80
 In
AIDS, Blastocystis hominis leads to chronic
diarrhea manifestations; six cases in Bahia (Brazil)
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were recently reported with parasite eradication
in the stool samples after specific treatment.
81
Blastocystis infection is common in
immunocompromised hosts and it may be diagnosed
through conventional techniques such as the Lutz
and Faust methods. There are reports in the literature
that show trichrome stains and Ficol concentrations
as alternatives for finding this parasite.
82,83
There is some controversy about the
appropriateness of treating this enteroparasitosis.
When treatment is chosen, metronidazole is used.
84
Cyclospora sp was initially isolated in 1870
by Eimer. The first report on its association with
AIDS dates back to March 1989, in a male patient
with chronic diarrhea.
85
Studies on the prevalence of cyclosporiasis
show very low rates, not higher than 1% in
developed countries.
86,87
Outbreaks of cyclosporiasis due to the
consumption of raspberries imported from
Guatemala occurred recently: 1465 cases were
reported from 20 states of the USA.
88
 Other
outbreaks were reported in Virginia (USA), due to
contamination of fresh basil, causing gastrointestinal
disease.
89
The diagnosis of infection by Cyclospora
cayatenensis is based upon the detection of oocysts
in fecal samples, via optical microscopy.
Cyclospora cayatenensis differs from
Cryptosporidium in its large size.
90
 Due to the
morphological similarities and lack of knowledge
on how to differentiate between these two species,
diagnosis of cyclosporidiosis is seldom
accomplished.
33
 It is essential to determine the
sporulation of Cyclospora, which may be done
using 2.5% potassium dichromate.
The low frequency of this protozoan may once
again be explained by the use of sulfamethoxazole-
trimethoprim administration as a prophylactic
treatment against Pneumocystis carinii in AIDS
patients presenting CD4+ cell counts lower than
200/mm
3
.
91,92
CONCLUSION
It can be noted that parasitosis presents a
very significant interface with AIDS, and this has
been the object of studies by many authors.
Investigations on the etiology of diarrhea in HIV-
infected patients indicate parasitosis as the cause
in up to 40% of patients.
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RESUMO
OBJETIVO: Relatar a importância das parasitoses intestinais em pacientes com Aids, mostrando dados relevantes na
literatura médica, com enfoque em especial, abordando a epidemiologia, diagnóstico e tratamento das enteroparasitoses,
principalmente da criptosporidíase, isosporíase, microsporidíase e estrongiloidíase. TIPO DE ESTUDO: Revisão narrativa.
PALAVRAS-CHAVE: HIV. AIDS. Parasitoses.
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